"Maybe even this???"
I couldn't open that link gassed but I think I got an idea of what it's about from the link. There does seem to be a lot of activity by the big pharmas in the ADC area.
Not to be outdone by its Big Pharma peers, Johnson & Johnson has fattened up its antibody-drug conjugate (ADC) pipeline via the acquisition of Ambrx Biopharma for $2 billion.
Link to the article below. I would be happy with a $2b offer for PAB. It would equate to a share price of around Ninety cents US -
J&J beefs up ADC pipeline by acquiring Ambrx for $2B (fiercebiotech.com)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.731M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 56 | 154590723 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 55843936 | 26 |
View Market Depth
| Last trade - 16.26pm 29/07/2025 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable